Evaluation of the Pathobiology of CALR-mutated MPN Cells

Recruiting now

Conditions studied: Myeloproliferative Neoplasm

In brief

The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.

Key facts

Study ID

NCT06480591

Run by

Wake Forest University Health Sciences

People needed

35

Starts

2025-01-21

Expected to finish

2027-09-01

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Written (or electronic) informed consent and HIPAA authorization for release of personal health information by participant or his/her legally authorized representative (LAR).
• Age ≥ 18 years at the time of enrollment
• Diagnosis of myeloproliferative neoplasm (MPN) according to 2022 World Health Organization classification of MDS/MPNs
• CALR-positive genetic mutation

You may not qualify if…

• Diagnosis of MPN with JAK2 V617F mutation

Where it is running

• Atrium Health Levine Cancer — Charlotte, North Carolina, United States (enrolling)
• Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.